Study of NXN 188 for the Treatment of Migraine With Aura

Status Completed

Clinical Trial Summary

NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.

Clinical Trial Description

This was a multicenter, double-blind, parallel group, active and placebo-controlled, three arm study of a single oral dose of NXN-188 for the treatment of acute migraine headache with aura.

After study eligibility was confirmed, subjects were randomized to NXN-188 600 mg, sumatriptan 100 mg, or placebo in a 1:1:1 ratio. Subjects left the clinic to self-administer the treatment at home at the onset of moderate to severe headache in a suitable dosing environment.

Treatment was not to exceed 42 days from Randomization. If the subject did not have a headache within 42 days of randomization (s)he did not take the study medication and returned it to the site. If the subject experienced a qualifying headache (s)he recorded the symptoms in a diary, dosed with the study drug, and called the IVRS to record assessments all adverse events and to report dosing. If the study drug provided insufficient relief 2 hours post dosing (s)he was permitted to use non-triptan rescue medication recommended by the investigator. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00920686
Study type	Interventional
Source	NeurAxon Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	June 2009
Completion date	March 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02253004` - Induction of Migraine Aura With Cilostazol	Phase 0
Recruiting	`NCT02202486` - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI	N/A
Completed	`NCT00123201` - Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache	Phase 2
Completed	`NCT04406649` - A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine	Phase 3
Completed	`NCT03874832` - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects	Phase 1
Recruiting	`NCT05565001` - The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	N/A
Recruiting	`NCT06459635` - Migraine Attack Pain Phase Prediction Study
Recruiting	`NCT05416476` - Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine	Phase 3
Active, not recruiting	`NCT02906085` - Endothelin-1 as a Potential Trigger of Migraine Aura	N/A
Recruiting	`NCT00893594` - Efficacy of Sumatriptan With Naprosyn in Migraine With Aura	N/A
Completed	`NCT01388699` - Migraine and Endothelial Dysfunction
Completed	`NCT00534560` - Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache	Phase 2
Terminated	`NCT04936061` - Transnasal Cooling for Migraine	N/A
Recruiting	`NCT05281770` - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Not yet recruiting	`NCT04063540` - Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura	Phase 2
Completed	`NCT03472417` - Partial Rebreathing in the Treatment of Migraine With Aura	N/A
Completed	`NCT00334178` - Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine	Phase 3
Recruiting	`NCT06051604` - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine	N/A
Recruiting	`NCT06414044` - Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Completed	`NCT03472378` - Can DFN-15 Terminate Migraine With Allodynia?	Phase 2